Poly (ADP‐ribose) polymerase‐inhibitors (PARPi) are currently applied for the treatment of HRR (BRCA1/2, BRD4, PTEN, or other HRR related genes) defective cancers such as ovarian cancer,7 pancreatic cancer,8 and prostate cancer.9 Here, PTEN is linked to cancer.